688321 Shenzhen Chipscreen Biosciences
- 20.96
- -0.14-0.66%
Shenzhen Chipscreen Biosciences News
Microchip Biotech (688321): Steady increase in revenue, positive clinical data
Microchip Biotech (688321): Phase II clinical data on siglitazide treatment for MASH was presented at the 2024AASLD conference
Microchip Biotech (688321): Rapid sales growth and innovation pipeline actively promoted
Microchip Biotech (688321): Continued development of new indications for sidabendamide and siglitazide entering the harvest period
Microchip Biotech (688321): Significant cost reduction and efficiency gains will soon usher in the DLBCL harvest period
Microchip Biotech (688321): Steady business performance and continuous promotion of core products
Microchip Biotech (688321): The expansion of the original innovative drug with multiple indications is expected to embark on a new journey of internationalization
Microchip Biotech (688321): Cidabendamide's colorectal cancer indications to be included in breakthrough treatments are expected to open up market space
Microchip Biotech (688321): Big Indications Drive High Growth, Cash Flow Turns Losses into Profits
Microchip Biotech (688321): It is expected to usher in multiple inflection points in valuation+performance+data in 24
Microchip Biotech (688321): 2024 enters the harvest year of Microchip's innovative drugs
Microchip Biotech (688321): 2024 enters the harvest year of Microchip's innovative drugs
Huafu Securities released a research report on April 18 stating that it gave Microchip Biotech (688321.SH) a purchase rating. The main reasons for the rating include: 1) the sales peak for sidabendamide hematomas is expected to exceed 1 billion dollars, a
Microchip Biology (688321): Sidabenamide is making a comeback with great potential for treating solid tumors
Microchip Biotech (688321): Expecting siglitat sodium dosage and cidabenamide DLBCL data
Microchip Biotech (688321): Revenue from two core products is growing steadily, and new indications have been accepted
Microchip Biotech (688321) Company's Dynamic Review: Sighlitazol successfully passed the National Conference Multi-Pipeline and clinical progress was progressing smoothly
Microchip Biotech (688321): Two major indications with strong revenue resilience under the pandemic Phase III enrollment completed
Microchip Biology (688321): High revenue growth, Sioroni small cell lung cancer clinical trial launched in the US
Microchip Biotech (688321) Company Follow-up Report: Pioneer Pipelines for Pioneer Drugs in China Are Gradually Abundant
Analysis
Price Target
No Data
No Data